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Abstract
Introduction: Polycystic Ovary Syndrome (PCOS) has a strong genetic background and the majority of patients with PCOS
have elevated BMI levels. The aim of this study was to determine to which extent BMI-increasing alleles contribute to risk of
PCOS when contemporaneous BMI is taken into consideration.
Methods: Patients with PCOS and controls were recruited from the United Kingdom (563 cases and 791 controls) and The
Netherlands (510 cases and 2720 controls). Cases and controls were of similar BMI. SNPs mapping to 12 BMI-associated loci
which have been extensively replicated across different ethnicities, i.e., BDNF, FAIM2, ETV5, FTO, GNPDA2, KCTD15, MC4R,
MTCH2, NEGR1, SEC16B, SH2B1, and TMEM18, were studied in association with PCOS within each cohort using the additive
genetic model followed by a combined analysis. A genetic allelic count risk score model was used to determine the risk of
PCOS for individuals carrying increasing numbers of BMI-increasing alleles.
Results: None of the genetic variants, including FTO and MC4R, was associated with PCOS independently of BMI in the
meta-analysis. Moreover, no differences were observed between cases and controls in the number of BMI-risk alleles present
and no overall trend across the risk score groups was observed.
Conclusion: In this combined analysis of over 4,000 BMI-matched individuals from the United Kingdom and the
Netherlands, we observed no association of BMI risk alleles with PCOS independent of BMI.
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Introduction
Polycystic ovary syndrome (PCOS) is the most common
endocrine disorder affecting up to 10% of females of reproductive
age. [1] PCOS itself as well as its separate phenotypic
characteristics demonstrate familial aggregation [2,3] and its
heritability has been estimated as high as 65%. [4] Key features of
the syndrome include ovulatory dysfunction, hyperandrogenism
and polycystic ovarian morphology. Moreover, the majority of
patients with PCOS have overweight or obesity. [5] It has been
well established that obesity worsens the phenotype of PCOS.
Lifestyle interventions and weight-loss not only improve body
composition and insulin resistance in patients with PCOS, they
also ameliorate the reproductive phenotype.[6–8] Although this
close relationship between PCOS and obesity clearly exists,
underlying mechanisms are far from being understood.
Obesity is also known to be a highly heritable trait [9,10] and its
genetics have been widely and successfully investigated using
genome wide association studies (GWASs).[11–15] Since patients
with PCOS have increased BMI levels compared to controls,
genetic variants influencing PCOS might well include BMI risk
alleles such that GWAS signals identified influencing PCOS might
in fact be driven by primary effects on BMI. Therefore, it is of
importance to evaluate whether adjustment or matching for BMI
would eradicate the potential for variants influencing BMI to have
an apparent effect on PCOS risk. If these effects remain after
taking case-control differences in BMI into consideration, it might
suggest either that a single BMI measurement is not an adequate
proxy for lifelong BMI when it comes to specifying the effects of
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BMI on PCOS, or that the BMI risk alleles have pleiotropic effects
on BMI as well as PCOS. The latter has been suggested for SNPs
mapping to the FTO gene in association with obesity and type 2
diabetes mellitus in Asians. [16,17].
Previous studies observed association of risk-alleles mapping to
the FTO and MC4R gene with PCOS and its phenotypic
characteristics.[18–23] However, these studies did not include
BMI-matched case-control sets and had relatively small sample
sizes (number of cases ranging from 65 to 800 and less than 1000
controls).
Therefore, we studied twelve BMI-associated loci in BMI-
matched case-control sets from two large university medical
centers to determine the effect on PCOS-susceptibility indepen-
dently of current BMI.
Materials and Methods
Ethics Statement
All clinical investigations were conducted according to the
guidelines in the Declaration of Helsinki. The study was approved
by the medical ethics committee from the Erasmus MC University
Medical Centre. Approval for the UK study was obtained from the
North Thames Multicenter Research Ethics Committee [MREC/
99/2/45]). All subjects provided fully written informed consent.
Subjects
Independent European PCOS populations from the United
Kingdom (UK) and the Netherlands were included in this study.
The UK case-control set included a total of 1354 women, of whom
563 were diagnosed with PCOS and 791 served as controls. The
case-control set from the Netherlands consisted of 510 patients
diagnosed with PCOS and 2720 control women from the general
population. BMI levels between cases and controls in both studies
were similar (p-value .0.05). Patients in both cohorts were
diagnosed according to 2003 Rotterdam criteria. [24] In
agreement with these criteria two of the following three symptoms
should be present: oligo-ovulation and/or anovulation with
gonadotropins levels within the normal limits, biochemical and/
or clinical hyperandrogenism and polycystic morphology of the
ovaries (PCOM). Oligomenorrhea was defined as a cycle length
over 35 days and amenorrhea as absence of menstrual bleeding.
Biochemical hyperandrogenism was determined by calculation of
the Free Androgen Index (FAI) as: 100 x T (nmol/L)/SHBG
(nmol/L). A FAI exceeding 4.5 was used as a cut-off. Clinical
hirsutism was assessed using the modified Ferriman-Gallwey score
and defined as an FG-score of at least 8. PCOM was assessed by
transvaginal ultrasound and defined as the presence of at least 12
follicles in one or both ovaries and/or increased ovarian volume
.10 ml. Exclusion criteria were presence of related disorders with
similar presentations such as Cushing’s disease and congenital
adrenal hyperplasia. The controls from the UK were population-
based and recruited as part of the UK Blood Services (UKBS) set
up by the Wellcome Trust Case Control Consortium (WTCCC).
[25] Control women from the Netherlands were derived from the
Rotterdam study, a population-based prospective cohort study.
[26] In brief, this is a large population-based study of elderly
subjects from a specific area near Rotterdam (Ommoord). All
women aged 45 years or older at onset of menopause and with
available DNA were included in the present analyses. These
population-based control groups provided reference groups of
allele frequencies which reflect the local general European
population, rather than being control groups wherein PCOS
specifically was excluded. Patients and controls were of European
descent.
Genotyping and Quality Control
Table S1 summarizes the studied SNPs mapping to BMI-
associated loci as identified by Frayling et al [11], Loos et al. [13],
Thorleifsson et al [14] and Willer et al. [15] These 12 loci were
established as genome wide significant between the years 2007–
2009 during the first waves of GWAS and have been replicated
across several ethnic populations ever since. [27] The studied
SNPs were the lead SNPs mapping to the BMI-associated loci, as
described in the aforementioned papers.[11,13–15] Genotyping
was carried out using Taqman ‘‘on demand’’-assays (Applied
Biosystems, Warrington, UK). The genotyping success rate was
.95%. The Rotterdam Study controls were genotyped using the
Illumina 550k array and imputed using HapMap2 CEU reference
panel. [28] Genotypes of six of the SNPs were derived from this
data: rs4074134 mapping to BDNF, rs7138803 mapping to
FAIM2, rs7647305 mapping to ETV5, rs10838738 mapping to
MC4R, rs10913469 mapping to SEC16B, rs7498665 mapping to
SH2B1. SNP rs11084753 had an imputation quality of 94%,
rs6548238 of 95% and all other SNPs had an imputation quality of
.99%. The other SNPs were genotyped using Taqman ‘‘on
demand’’-assays (Applied Biosystems, Warrington, UK). None of
the SNPs deviated from Hardy-Weinberg equilibrium (HWE).
Statistical Analysis and Power Calculation
Association analyses were initially carried out within each case-
control set separately. The additive genetic model was tested using
PLINK (v.1.07) [29] and IBM SPSS version 20 (IBM Statistical
Package for the Sociological Sciences Inc., Chicago, USA). The
combined effect of the BMI-increasing alleles in the two
populations was evaluated using a fixed-effects meta-analysis in
GWAMA [30] for SNPs with heterogeneity (I2) less than 25%.
When I2 exceeded 25%, a random effect meta-analysis was
performed using statistical software package R (http://www.r-
project.org). Moreover, we studied the association of BMI-
increasing alleles with PCOS when only including individuals
with a BMI $30 kg/m2 and in a second analysis when only
including individuals with a BMI ,30 kg/m2.
Using Genetic Power Calculator software we determined that
with the sample size of the total case control set (cases: n = 1073;
controls: n = 3511), we reached approximately 95% power to
detect association of a risk allele of frequency $0.2 having an odds
ratio of $1.3 and an alpha of 0.05 (http://pngu.mgh.harvard.
edu/˜purcell/gpc/). [31] Since we selected the genetic variants, we
did not correct for multiple testing and a P value ,0.05 was
considered statistically significant.
To test for the combined effect of all the BMI-associated alleles
on PCOS susceptibility and to estimate the genetic risk of having
PCOS for these women dependent on the number of BMI-
increasing alleles present, we calculated the Genetic Risk Score
(GRS). The GRS was modeled as a continuous variable and the
calculation was carried out using R (http://www.r-project.org/).
Using the GRS we assume that each SNP in the panel contributes
equally to PCOS risk and that each individual allele has an equal
and additive effect on risk. To obtain accurate counts of BMI-
increasing alleles, only individuals with genotypes for at least 90%
of SNPs (11 out of 12) were included. Based on this criterion, a
total of 1264 individuals, i.e., 512 cases and 752 controls, from the
UK and 3150 individuals from the Netherlands, i.e., 502 cases and
2648 controls, were included in the GRS-analysis. This method
was described previously. [32,33] Missing genotypes were replaced
with the average risk score for each SNP in the total population.
The maximum attainable score was 24 BMI-increasing alleles (12
SNPs * 2 alleles). The reference group was defined as 12 to 13
BMI-increasing alleles, which was the mean number of BMI-
BMI-Associated Alleles in PCOS
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increasing alleles present in the controls. Analyses were carried out
within the separate case-control sets as well as in the combined set.
Finally, we calculated the overall trend across the GRS-groups
using the Kruskal Wallis trend test (IBM SPSS version 20).
Results
The UK cases had a mean BMI of 26.0 kg/m2 (610.9 SD) and
the controls had a BMI of 25.9 kg/m2 (64.57 SD), whereas the
cases from the Netherlands had a median BMI of 26.4 kg/m2
(IQR 22.4–31.7) and the controls had a BMI of 26.3 kg/m2 (IQR
23.97–29.1). The prevalence rates of normal weight, overweight
en obese individuals are depicted in Table 1. Although the BMI
levels of the total group of cases and controls were similar in the
samples from the UK as well as the Netherlands, these prevalences
were significantly different (P,0.001). Therefore, we also ran
separate analyses including only individuals with BMI $30 kg/m2
and including only individuals with a BMI ,30 kg/m2. Allele
frequencies of the BMI-risk alleles in the cases and controls of both
case-control sets are reported in Table S2.
First, we tested whether carrying BMI-associated alleles
influenced PCOS susceptibility in cases and controls who were
of similar BMI (Table 2). SNP rs7498665 mapping to the SH2B1
locus was significantly associated with a decreased risk of having
PCOS (OR =0.79; 95%CI: 0.69–0.90, P =0.001) in the case-
control set from the Netherlands. No such association was evident
in the case-control set from the UK (OR =1.04; 95% CI: 0.88–
1.22, P =0.64) or in the random effects meta-analysis. Moreover,
none of the other SNPs was significantly associated with PCOS,
neither in the separate UK and Dutch analysis nor in the meta-
analysis. The BMI-increasing alleles were not associated with
PCOS in the meta-analysis including only individuals with
BMI,30 kg/m2, nor were they associated with PCOS in the
BMI $30 kg/m2 group (Table S3 and Table S4, respectively).
To determine whether the overall burden of BMI-increasing
alleles was associated with PCOS status in these samples, a GRS
was constructed (Figure 1, Table 3). The individuals carrying less
than 8 BMI-associated alleles and individuals carrying over 18
BMI-associated alleles together account for a very small propor-
tion of the total population, i.e., 2.6%. None of the GRS-groups
was attributed more often to patients with PCOS compared with
the reference GRS-group. Moreover, no overall trend in carrying
an increasing number of BMI-associated alleles on PCOS
susceptibility was observed neither for the total case-control set
(P =0.44), nor for the separate case-control sets from the UK (P
= 0.97) or the Netherlands (P =0.17).
Discussion
In this combined analysis including .4,000 patients with PCOS
and controls from the United Kingdom and the Netherlands, we
observed no association of genetic BMI-risk loci with PCOS when
contemporaneous BMI is similar in cases and controls.
The last two years, genome wide association studies (GWASs)
have emerged to identify genetic risk factors for PCOS. Two large
studies identifying such PCOS-susceptibility loci in Han-Chinese
patients have been published [34,35] while GWAS in patients
from Northern European ancestry are in progress. In the current
study, we observed no systematic effect of the BMI-associated
alleles on PCOS susceptibility in our BMI-matched case-control
set. This infers that adjustment or matching for BMI will
disentangle BMI-associated genetic signals to show up in PCOS
GWAS and seems therefore not a genuine concern in the previous
and upcoming GWASs in PCOS.
Presence of an increasing number of BMI-raising alleles is
associated with an increased genetic predisposition to obesity. To
determine the overall burden of BMI-associated alleles on risk for
PCOS we calculated a counted genetic risk score and compared
PCOS risk across such BMI risk groups. By doing so, we assumed
that each allele has an equal and additive effect on PCOS risk. In
practice some SNPs will have stronger effects than others.
However, when the ORs are small as they are in our study, using
a counted genetic risk model is appropriate. [32,36] None of the
GRS-groups was attributed more often to the patients diagnosed
with PCOS than controls compared to the reference GRS-group.
Moreover, no overall trend across the consecutive GRS groups
was observed, strengthening the results from the allelic-association
analysis that BMI-associated alleles seem not to have pleotropic
effects on PCOS risk. Increased BMI levels and weight in PCOS
seem to be mediated by other genetic factors determining an
individual’s susceptibility to become obese or through modifying
environmental effects. It has been shown that although women
with PCOS reported a better, more healthy, dietary intake they
seem to have an increased energy intake in combination with an
increased sitting time without any discernible differences in total
physical activity compared to women without PCOS. [37]
Moreover, also in patients with PCOS, higher energy intake and
glycemic index and lower physical activity, as well as age, smoking,
alcohol intake, occupation, education and country of birth, were
independently associated with BMI. [38].
In the current study we included population-based controls.
Selection of controls in genetic studies is an extensively discussed
issue. The main argument for using so-called ‘super controls’, i.e.,
individuals who are known to be unaffected, instead of population-
based controls, is that the power is expected to improve because
the difference in allele frequency between cases and controls is
increased. For a disease as frequent as PCOS this would indeed
increase the power to detect effects. However, only small samples
of control women for whom PCOS is excluded are available.
Moreover, these women are selected based on other criteria, for
example tubal infertility. Consequently, it is more feasible to use a
larger sample which is randomly selected from the general
Table 1. The prevalence rates of normal weight, overweight en obese patients with PCOS and controls.
The United Kingdom P The Netherlands P
% cases % controls % cases % controls
Normal weight BMI ,25 42.7 50.3 ,0.001 43.9 35.2 ,0.001
Overweight BMI $25 and ,30 17.6 32.4 22.2 45.5
Obese BMI $30 39.7 17.3 33.9 19.3
BMI Body Mass Index; P p-value.
doi:10.1371/journal.pone.0087335.t001
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population as controls [39–41] and thereby compensating for the
fact that we might also have also included women diagnosed with
PCOS.
A potential limitation of the current study is that we matched
BMI based on a single measurement. In general the BMI of men
as well as in women increases throughout life. Therefore, a single
BMI measurement may not be an appropriate proxy for lifetime
BMI and might be a poor estimate of the long-standing effects of
BMI on PCOS risk. However, since we observed no systematic
effect of BMI-associated alleles on PCOS risk in our matched case-
control set, this seems not to have influenced our results
tremendously. It has been previously observed that the association
of genetic variants in FTO and MC4R with BMI and weight
strengthen during childhood up to age 20 years and then become
weaker with increasing age during adulthood. [42] Therefore, as
has been suggested for phenotypes associated with type 2 diabetes
mellitus [17], longitudinal studies are needed to adequately
explore the complex and dynamic nature of BMI-associated
alleles on cardiometabolic characteristics in PCOS.
In conclusion, we have shown in two independent large PCOS
case-control sets matched for BMI, that there is no systematic
effect of BMI-associated alleles on PCOS risk suggesting that these
alleles do not have a pleiotropic effect on PCOS susceptibility.
Hence, adjusting for BMI in PCOS case-control GWAS studies
should be an effective strategy for removing confounding effects of
BMI on the association of other genetic variants and PCOS.
Figure 1. Combined impact of risk alleles on the risk of having PCOS compared to the reference risk group. Along the X-axis the risk
categories are shown based on the number of BMI-increasing alleles. The histogram (Y-axis on the left) indicates the percentage of individuals for
each risk-score group. The odds ratio and confidence intervals calculated based on the risk of having PCOS compared to the reference risk group are
plotted on the Y axis on the right.
doi:10.1371/journal.pone.0087335.g001
Table 3. Combined impact of BMI-increasing alleles on the risk of having PCOS.
United Kingdom The Netherlands Combined
GRS
Cases
n (%)
Controls
n (%) OR (95%CI)
Cases
n (%)
Controls
n (%) OR (95%CI) Cases n (%)
Controls
n (%) OR (95%CI)
,8 7 (1.4) 14 (1.9) 0.73 (0.29–1.86) 4 (0.8) 31 (1.2) 0.82 (0.28–2.34) 11 (1.1) 45 (1.3) 0.90 (0.46–1.76)
8 to 9 49 (9.6) 78 (10.4) 0.92 (0.61–1.38) 37 (7.4) 191 (7.2) 1.22 (0.83–1.81) 86 (8.5) 269 (7.9) 1.18 (0.90–1.55)
10 to 11 121 (23.6) 177 (23.5) 1.00 (0.74–1.36) 136 (27.1) 611 (23.1) 1.41 (1.09–1.81) 257 (25.3) 788 (23.2) 1.20 (1.00–1.45)
12 to 13 173 (33.8) 254 (33.8) Reference 146 (29.1) 922 (34.8) Reference 319 (31.5) 1176 (34.6) Reference
14 to 15 125 (24.4) 171 (22.7) 1.07 (0.79–1.45) 129 (25.7) 641 (24.2) 1.27 (0.98–1.64) 254 (25.0) 812 (23.9) 1.15 (0.96–1.39)
16 to 17 32 (6.3) 52 (6.9) 0.90 (0.56–1.46) 40 (8.0) 216 (8.2) 1.17 (0.80–1.71) 72 (7.1) 268 (7.9) 0.99 (0.74–1.32)
.18 5 (1.0) 6 (0.8) 1.22 (0.37–4.01) 10 (2.0) 36 (1.4) 1.75 (0.85–3.61) 15 (1.5) 42 (1.2) 1.32 (0.72–2.41)
Data are presented for pools of BMI-increasing alleles as odds ratio and confidence intervals. Only individuals with data of .90% of the SNPs available were included.
The mean number of BMI-increasing alleles in the controls was used as the reference group. GRS genetic risk score; n number of individuals; OR odds ratio.
doi:10.1371/journal.pone.0087335.t003
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